Harrow Health, Inc. (Nasdaq: HROW) announced today the launch of its new Harrow Access for All (HAFA) program, expanding the company’s existing VEVYE Access for All initiative to cover its full portfolio of branded, generic, and compounded ophthalmic medications. The program will become available in late 2025 through the HarrowAccess.com portal and is slated to expand into 2027, providing a single, unified access point for prescribers and patients.
The HAFA platform is designed to remove financial and logistical barriers by integrating prescriptions directly into providers’ electronic medical record systems, eliminating the need for copay cards or additional paperwork. All medications under the program are dispensed through PhilRx, Harrow’s specialty pharmacy partner, with convenient home delivery and no extra steps for patients. CEO Mark L. Baum described the initiative as “the Amazon for Ophthalmology,” emphasizing the company’s commitment to patient‑first access and streamlined care.
By extending the proven success of VEVYE Access for All—where VEVYE prescriptions grew 66% in Q2 2025—HAFA positions Harrow to increase prescription volumes across its entire product line. The program’s focus on affordability, ease of prescribing, and predictable access is expected to drive higher utilization, improve patient outcomes, and support the company’s broader growth strategy in the ophthalmic market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.